EUVIMEDEUVIMED entdecken
Crossref

Modeling the Pretest Probability of Identifying Druggable Mutations in Lung Cancer Using Nationwide Comprehensive Genomic Profiling Data

Hiroaki Ikushima iD, Kousuke Watanabe, Aya Shinozaki-Ushiku, Satoshi Kodera, Norihiko Takeda, Katsutoshi Oda iD, Hidenori Kage iD

JCO Clinical Cancer Informatics · 2026

DOI: 10.1200/cci-25-00269 ↗

Kurz gefasst

Fachartikel in der Zeitschrift JCO Clinical Cancer Informatics, 2026. Verfasst von Hiroaki Ikushima und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Respiratory Medicine, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan. Hauptthemen laut MEDLINE: Lung Neoplasms, Mutation, Genomics, Biomarkers, Tumor. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 43 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE Comprehensive genomic profiling (CGP) is a key strategy in precision medicine for lung cancer, yet its clinical implementation remains limited, partly because of the uncertainty in identifying druggable mutations in individual patients. In this study, we investigated the potential of an artificial intelligence (AI)–based tool to predict the probability of identifying druggable mutations before CGP (pretest probability). METHODS We developed an eXtreme Gradient Boosting (XGBoost) prediction model trained on pre-CGP clinical variables from 3,470 patients with lung cancer (June 2019-November 2023) to estimate the probability of identifying druggable mutations. The key predictors were identified using explainable artificial intelligence (XAI) analysis. The refined model was deployed as a web application and evaluated in a temporally independent test cohort of 1,307 patients (December 2023-November 2024), with Brier score as the primary end point. RESULTS The prediction model achieved an area under the receiver operating characteristic curve (AUROC) of 0.85 (95% CI, 0.82 to 0.89) in the overall validation cohort and 0.79 (95% CI, 0.74 to 0.84) in patients for whom a driver mutation had not been identified through companion diagnostic testing. The XAI analysis identified sex, smoking history, histology, and metastatic sites as important predictors. Even among patients who underwent tissue CGP, bone ( P = .011) and lung ( P < .001) metastases were significantly associated with a higher druggable mutation detection rate. The deployed model achieved Brier scores of 0.19 in the overall independent test cohort and 0.16 in patients for whom a driver mutation had not been identified through companion diagnostic testing. CONCLUSION These findings indicate that an AI-based tool using pre-CGP clinical data may support broader CGP implementation and improve access to targeted therapies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lung NeoplasmsMutationGenomicsBiomarkers, TumorHumansFemalePrecision MedicinePrediction AlgorithmsMaleArtificial IntelligenceBoosting Machine Learning AlgorithmsProbability

Substanzen

Biomarkers, Tumor

Autor:innen und Institutionen

  • Department of Respiratory Medicine, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
  • Next-Generation Precision Medicine Development Laboratory, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
  • Division of Integrative Genomics, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
  • Department of Pathology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
  • Department of Cardiovascular Medicine, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.

ORCID-Profile: Hiroaki Ikushima, Katsutoshi Oda, Hidenori Kage

Zitieren

APA

Ikushima, H., Watanabe, K., Shinozaki-Ushiku, A., Kodera, S., Takeda, N., Oda, K., & Kage, H. (2026). Modeling the Pretest Probability of Identifying Druggable Mutations in Lung Cancer Using Nationwide Comprehensive Genomic Profiling Data. JCO Clinical Cancer Informatics. https://doi.org/10.1200/cci-25-00269

Vancouver

Ikushima H, Watanabe K, Shinozaki-Ushiku A, Kodera S, Takeda N, Oda K, et al. Modeling the Pretest Probability of Identifying Druggable Mutations in Lung Cancer Using Nationwide Comprehensive Genomic Profiling Data. JCO Clinical Cancer Informatics. 2026. doi:10.1200/cci-25-00269

BibTeX
@article{Ikushima2026,
  author = {Ikushima, Hiroaki and Watanabe, Kousuke and Shinozaki-Ushiku, Aya and Kodera, Satoshi and Takeda, Norihiko and Oda, Katsutoshi and Kage, Hidenori},
  title = {Modeling the Pretest Probability of Identifying Druggable Mutations in Lung Cancer Using Nationwide Comprehensive Genomic Profiling Data},
  journal = {JCO Clinical Cancer Informatics},
  year = {2026},
  doi = {10.1200/cci-25-00269}
}
Kostenlos starten →